Metoprololsuccinat Teva

Metoprolol succinate, the active ingredient in Metoprololsuccinat Teva, is a beta blocker presented as an oral tablet for oral use. It lowers blood pressure, relieves angina, and improves outcomes in heart failure and after myocardial infarction. It is indicated for adults with cardiovascular conditions and is marketed in the European Union.

GNH USA supplies Metoprololsuccinat Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global logistics.

Metoprolol succinate is a selective β1‑adrenergic blocker used in several cardiovascular disease categories.

- Hypertension: reduces systolic and diastolic blood pressure to target levels. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Chronic heart failure: improves left‑ventricular function and reduces hospitalisation risk. - Post‑myocardial infarction prophylaxis: lowers the chance of recurrent cardiac events.

Metoprolol succinate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: light‑headedness, especially when standing. - Headache: mild to moderate intensity. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced peripheral circulation. - Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe bradycardia: heart rate dropping to dangerously low levels. - Hypotension: marked drop in blood pressure causing faintness. - Heart block: impaired electrical conduction in the heart. - Bronchospasm: narrowing of airways, especially in asthmatic patients. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Depression or mood changes: emerging or worsening depressive symptoms.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Heart rate assessment: watch for bradycardia, especially in patients with conduction disorders. - Respiratory review: avoid use in patients with active bronchospastic disease. - Renal/hepatic function: dose may need adjustment in impairment. - Discontinuation: taper gradually to prevent rebound hypertension or tachycardia. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Metoprolol succinate can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other beta blockers: additive negative chronotropic effects. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): risk of severe bradycardia and AV block. - Clonidine: abrupt withdrawal may cause hypertensive crisis. - Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: can enhance hypotensive response. - ACE inhibitors or ARBs: monitor for excessive blood pressure reduction. - Antidepressants (e.g., SSRIs): may increase plasma metoprolol levels. - Antiarrhythmic agents: potential for conduction disturbances.